Joslin Diabetes Center is a leader in continuing education for healthcare professionals. Joslin's CME and CE activities promote the highest standards of care, drawing on up-to-date medical literature as well as cutting-edge research conducted at Joslin to provide current, relevant, and evidence-based findings from Joslin faculty and other experts. Our mission is to help providers offer their patients optimal management of diabetes and its related conditions, improved health outcomes, and enhanced quality of life.
Upcoming Live Activities
Join us for the series The Evolution of Insulin Replacement: New Perspectives and Clinical Applications
Presented by Joslin Diabetes Center in Joint Providership with PlatformQ Health Education, LLC. All sessions will be held as video webinars online. We will post the link to register for these activities shortly.
Thursday, September 14, 2017, from 3:00 PM EST – 4:00 PM EST
• Insulin Options for Diabetes: Update on their Evolution
Thursday, October 19, 2017, from 1:00 PM EST – 2:00 PM EST
• Advancing to Insulin Therapy for Type 2 Diabetes: The Impact of the New Insulin Options
Thursday, November 30, 2017, from 12:00 PM EST – 2:00 PM EST
• 12:00 PM – 1:00 PM EST: Physiologic Insulin Replacement: Practical Approaches for the Primary Care Provider
• 1:00 PM – 2:00 PM EST: The Evolution of Glycemic Monitoring and Insulin Delivery Devices: Why the Primary Care Provider Should Understand the Options
These activities are supported by educational grants from Novo Nordisk Inc. and Medtronic, Inc.
Current Enduring Activities
Click on the title of each activity to begin.
Topics Of Interest:
• Pathophysiology and clinical manifestations of insulin resistance
• Pharmacokinetics and pharmacodynamics of concentrated insulins used to treat people with diabetes, particularly in patients with insulin resistance
• Indications and use of concentrated insulins in patients with type 2 diabetes
• Identification of patient, provider, and health care system barriers to the use of concentrated insulins, and methods to overcome these barriers
This activity is supported by an educational grant from Lilly USA, LLC and is offered through our partner Platform Q Health. Expiration date: December 21, 2017.
Virtual Grand Rounds Series: Dyslipidemia and Diabetes
Topics of Interest:
• Key changes in the updated treatment guidelines for dyslipidemia
• Strategies to address residual CV risk beyond statin therapy
• Indications for newer non-statin drug therapies in patients with high lipid–related CVD risk
• Pharmacology, approved indications, and optimal use of PCSK9 inhibitors in patients at high risk for CVD events
This activity is supported by an educational grant from Amgen and is offered through our partner Platform Q Health. Expiration date: September 29, 2017.
Proven Success with Educational Outcomes
Joslin Diabetes Center has been at the forefront of measuring educational outcomes for our activities, based on the levels defined by Moore et al.1 We have been involved in several specific projects that measure the impact of our educational activities on clinician performance measures (Level 5) and patient outcomes measures (Level 6). Please click here to read about one of these initiatives entitled Targeting Type 2 Diabetes: Achieving Glycemic and Cardiometabolic Goals. This initiative was supported by educational grants from GlaxoSmithKline LLC and Merck Sharpe and Dohme Corp.
1 Moore DE Jr, Green JS, Gallis HA. Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities. J Contin Educ Health Prof. 2009;29(1):1-15.
Joslin at World Congress for CPD 2016
Joslin recently presented a session and a poster based on the performance improvement grant entitled Comparison of Methods for Assessing Clinical Performance Improvement in Primary Care.View the poster here
Joslin Clinical Guidelines
To assist physicians and other healthcare professionals in managing the care of their patients with diabetes, Joslin offers approved clinical guidelines on a variety of topics including Adult Diabetes, Pharmacological Management of Type 2 Diabetes, and Continuous Glucose Monitors.